LLY Eli Lilly And Company976.07+41.47 (+4.4%)
LLY Eli Lilly And Company919.23+68.02 (+8.0%)
Outlook is neutral, with stock confined to a range of ±5%
Strategy has +44% ROI potential and 6% overvalued
LLY Eli Lilly And Company973.88+54.11 (+5.9%)
Outlook is neutral, with stock confined to a channel of ±4%
Strategy has +68% ROI potential and 11% overvalued